The Russian pharmaceutical firm Pharmasyntez and the Chinese biologics developer Hualan Bio have entered into a memorandum of strategic cooperation.
According to a press release related to the event (available to GxP News), the partners will “share key technologies and collaborate to develop new high-tech biologics in the fields of pharmaceuticals and industrial biotechnology.”
The agreement involves a technology transfer, whereby Hualan Bio will grant access to its platforms for the development of biological products. This collaboration will enable us to jointly develop new effective drugs, including therapeutic monoclonal antibodies for treating cancer, autoimmune disorders, and infectious diseases. The document includes a section on localization of production, indicating that some biologics will be manufactured at Pharmasyntez facilities in Russia. Furthermore, the parties intend to collaborate on entering global markets, “registering and bringing the developed drugs to market within the Eurasian Economic Union as well as internationally.”
“Firstly, the cooperation will speed up the integration of Hualan’s achievements in biotechnology into industrial production and reduce the time required for Pharmasyntez to move from development to clinical application. Secondly, it allows for the combination of complementary advantages: Hualan will leverage its advanced manufacturing and scientific innovations, while Pharmasyntez will draw on its extensive clinical expertise and market resources, fostering mutually beneficial development,” said Wenqi An, Director of Hualan Genetic Engineering.
Earlier it was reported that Pharmasyntez is planning a joint project with another Chinese company, Yangtze River Pharmaceutical.
